Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen to launch US Eylea biosimilar
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of App
District Court Denies Regeneron’s Motion For Preliminary Injunction To Block Amgen’s Eylea Biosimilar
On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s (“Regeneron”) motion for
RBC would buy Regeneron on weakness with biosimilar Eylea priced in
RBC Capital notes that it was announced that the Court of Appeals denied Regeneron’s (REGN) motion for an emergency injunction and the
Regeneron loses bid to block Amgen's Eylea biosimilar launch in US
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.
14h
Regeneron drops after court rejects request for temporary injunction for Eylea generic
Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...
8d
on MSN
Amgen’s stock falls as analyst warns that hype around obesity drug is baked in
Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.
1d
Cautious Outlook for Amgen’s MariTide: Awaiting Key Differentiation Data
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Amgen (AMGN – Research Report) and keeping the price target at ...
4d
on MSN
Is Amgen Stock a Buy?
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.
5d
Amgen's $11 Billion Transfer Pricing Dispute Draws Investor Suit
An investor is suing Amgen Inc.'s leaders over the company’s $10.7 billion fight with the IRS, which has said the ...
1d
Amgen’s Growth Potential Affirmed: Buy Rating with Increased Price Target to $383
TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $383.00. Yaron ...
STAT
4d
Amgen, Biogen and Takeda talk about R&D on tough targets
At the STAT summit, executives discuss their challenges, and hopeful signals, about breaking into markets on obesity and ...
1d
Amgen Inc. (NASDAQ:AMGN) Shares Sold by OLD National Bancorp IN
OLD National Bancorp IN lessened its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.0% during the 3rd ...
devdiscourse
9h
Health Updates: From Biosimilars to Bird Flu
Recent health news includes Amgen's launch of an Eylea biosimilar in the U.S., Slovakia's bird flu outbreak, and China's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Regeneron
NASDAQ
Trade
Eylea
Aflibercept
Feedback